DelveInsight has launched a new report on “Cholangiocarcinoma – Market Insights, Epidemiology, and Market Forecast-2032”.
DelveInsight’s “Cholangiocarcinoma – Market Insights, Epidemiology, and Market Forecast-2032″report delivers an in-depth understanding of the Cholangiocarcinoma, historical and forecasted epidemiology as well as the Cholangiocarcinoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the key facts of the Cholangiocarcinoma Market Report:
- As per DelveInsight estimates, the total diagnosed incident population of Cholangiocarcinoma (CCA) in the 7MM ranges 18,470 in 2019. Among all the countries, the estimates show a higher incidence of Cholangiocarcinoma (CCA) in the United States with 6,768 cases in 2019.
- Among the EU5 countries, Germany had the highest incident population of Cholangiocarcinoma (CCA) with 4,471 cases, followed by Italy and the United Kingdom. On the other hand, Spain had the lowest incident population. As per our estimates, Japan had 4,287 incident cases of Cholangiocarcinoma (CCA) in 2019.
- As per DelveInsight insights, the incidence rate varied based on type-specific cases and the estimates showed an increasing trend in the Intrahepatic CCA cases, while Extrahepatic CCA showed a decreasing trend or in some are stable cases.
Key benefits of the report:
- Cholangiocarcinoma market report covers a descriptive overview and comprehensive insight of the Cholangiocarcinoma epidemiology and Cholangiocarcinoma market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
- The Cholangiocarcinoma market report provides insights on the current and emerging therapies.
- Cholangiocarcinoma market report provides a global historical and forecasted market covering drug outreach in 7MM.
- The Cholangiocarcinoma market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Cholangiocarcinoma market.
Got queries? Click here to know more about Cholangiocarcinoma Market Landscape.
Cholangiocarcinoma Overview
A cancer in the slender tubes that carry bile, the digestive fluid, through the liver. It’s a rare but aggressive form of cancer.Symptoms include yellow skin and eyes (jaundice), intensely itchy skin and stool that’s white in colour.Treatment may include surgery, chemotherapy and radiation.
The key players driving the Cholangiocarcinoma market:
- Janssen Pharmaceutica
- Roche
- Loxo Oncology/ Bayer
- Bayer
- Basilea Pharmaceutica
- Delcath Systems
- QED Therapeutics
- Incyte Corporation
- Agios Pharmaceuticals
- And others
The launch of the emerging therapies is expected to significantly impact the Cholangiocarcinoma treatment scenario in the upcoming years.
Drug covered:
- Erdafitinib
- Entrectinib
- Larotrectinib
- Regorafenib
- Derazantinib
- Melphalan
- Infigratinib
- Pemigatinib
- Vosidenib
- And others.
Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Cholangiocarcinoma Patient Share (%) Overview at a Glance
5. Cholangiocarcinoma Market Overview at a Glance
6. Cholangiocarcinoma Disease Background and Overview
7. Cholangiocarcinoma Epidemiology and Patient Population
8. Country-Specific Patient Population of Cholangiocarcinoma
9. Cholangiocarcinoma Current Treatment and Medical Practices
10. Unmet Needs
11. Cholangiocarcinoma Emerging Therapies
12. Cholangiocarcinoma Market Outlook
13. Country-Wise Cholangiocarcinoma Market Analysis (2019–2032)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Cholangiocarcinoma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/